Testing an MDM2 drug plus an immune therapy for advanced tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can provide informed consent (or if you are pregnant, the trial requires not being pregnant and not breastfeeding).
- You are well enough for treatment (performance status about fully active to limited: ECOG 0–1).
- Your cancer is confirmed by biopsy and is either advanced liposarcoma that has progressed, or an advanced solid tumor; for the liposarcoma part of the study, the tumor must be TP53 “wide-type” and have MDM2 “amplification.”
- You have tumors that can be measured by CT or MRI, and your expected survival is more than 12 weeks.
- Your blood counts and organ function are adequate (for example, enough white blood cells, platelets, hemoglobin, liver and kidney levels without needing ongoing supportive transfusions or growth factors).
- You have not had certain prior treatments or immune side effects: no prior MDM2–p53 inhibitor, no serious past allergic reaction to PD-1/PD-L1 drugs, and no previous high-grade immune side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs – mirdametinib and palbociclib – taken as pills for people with a specific aggressive type of liposarcoma (dedifferentiated liposarcoma) that has spread or can't be removed. The goal is to see if this combination can shrink or slow the tumor.
This study tests a combination of two drugs (LM-108 and toripalimab) for people with advanced solid tumors that have a specific marker called MSI-H or dMMR. It is for those whose cancer has grown after previous immunotherapy treatment.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
This trial tests a new combination of two drugs (LTC004 and toripalimab) for people with advanced solid tumors that have stopped responding to standard immunotherapy. It aims to see if this combination can help when immunotherapy alone no longer works.
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Liposarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.